ALLO vs. NMRA, BCRX, NVAX, IMCR, MESO, BLUE, VIR, ADPT, PSTX, and IMTX
Should you be buying Allogene Therapeutics stock or one of its competitors? The main competitors of Allogene Therapeutics include Neumora Therapeutics (NMRA), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Immunocore (IMCR), Mesoblast (MESO), bluebird bio (BLUE), Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Poseida Therapeutics (PSTX), and Immatics (IMTX). These companies are all part of the "biological products, except diagnostic" industry.
Allogene Therapeutics vs.
Allogene Therapeutics (NASDAQ:ALLO) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Allogene Therapeutics received 259 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 91.30% of users gave Neumora Therapeutics an outperform vote while only 65.57% of users gave Allogene Therapeutics an outperform vote.
Allogene Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 3.34, meaning that its stock price is 234% more volatile than the S&P 500.
In the previous week, Neumora Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 8 mentions for Neumora Therapeutics and 7 mentions for Allogene Therapeutics. Neumora Therapeutics' average media sentiment score of 0.68 beat Allogene Therapeutics' score of 0.54 indicating that Neumora Therapeutics is being referred to more favorably in the news media.
Neumora Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. Neumora Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.
Allogene Therapeutics currently has a consensus target price of $9.73, indicating a potential upside of 412.28%. Neumora Therapeutics has a consensus target price of $23.40, indicating a potential upside of 129.86%. Given Allogene Therapeutics' higher probable upside, equities research analysts clearly believe Allogene Therapeutics is more favorable than Neumora Therapeutics.
Neumora Therapeutics has a net margin of 0.00% compared to Allogene Therapeutics' net margin of -223,139.98%. Allogene Therapeutics' return on equity of -52.13% beat Neumora Therapeutics' return on equity.
83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 26.4% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Allogene Therapeutics beats Neumora Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Allogene Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALLO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Allogene Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ALLO) was last updated on 12/18/2024 by MarketBeat.com Staff
Free ALLO Stock Alerts